Millions of people worldwide have heart failure. Despite enormous advances in care that have improved outcome, heart failure remains associated with a poor prognosis. Worldwide, there is poor short-term and long-term survival. The 1 year survival following a heart failure admission is in the range of 20–40% with between-country variation. For those living with heart failure, the symptom burden is high. Studies report that 55 to 95% of patients experience shortness of breath and 63 to 93% experience tiredness. These symptoms are associated with a high level of distress (43–89%). Fewer patients experience symptoms such as constipation (25–30%) or dry mouth (35–74%). However, when they do, such symptoms are associated with high levels of distress (constipation: 15–39%; dry mouth: 14–33%). Psychological symptoms also predominate with possibly as many as 50% experiencing depression. Palliative care services in heart failure are not widely available. Even in countries with well-developed services, only around 4% of patients are referred for specialist palliative care. Many patients and their families would benefit from receiving specialist palliative care support.

*Correspondence to: Jillian P. Riley, National Heart and Lung Institute, Imperial College, London, UK. Email: jillian.riley@imperial.ac.uk
extending therapies, the treatment focus of palliative care lies more in maintaining or improving the quality of remaining life and best ensuring a comfortable and dignified death when that outcome becomes inevitable. Although palliative care is often perceived as synonymous with end-of-life care, the key concepts have been accepted as equally relevant throughout any chronic disease trajectory from the point of diagnosis until death (see Box 1).

**Box 1. Goals of palliative care (adapted from World Health Organization, 2014. Global Atlas of Palliative Care)**

Palliative care is as follows:

- affirms life and regards dying as a normal process;
- offers a support system to help patients live as actively as possible until death;
- offers a support system to help the family cope during the patient’s illness and in their own bereavement;
- uses a team approach to address the needs of patients and their families that includes bereavement counselling;
- enhances quality of life and may also positively influence the course of illness; and
- is applicable early in the course of illness, in conjunction with other therapies that are intended to prolong life and includes investigations needed to understand and manage distressing clinical complications.

Despite modern advances in treatment, the diagnosis of heart failure confers a significant mortality risk. Data from national registries highlight poor short-term and long-term survival and suggest a within-hospital death rate of between 4 and 10%. Following a heart failure hospital admission, the 1 year death rates are reported in the range of 20 to 40%, with variation in these data between individual healthcare systems. In the UK, the National Heart Failure Audit collates and analyses data on patients admitted to national health service hospitals in England and Wales with new acute heart failure or decompensated chronic heart failure. Data between April 2013 and March 2014 on 54,654 episodes, representing 85% of all heart failure admissions over that period, demonstrate an overall in-hospital mortality of 9.5% rising to 12% for those aged >75 years. These trends remain largely unchanged over the previous 5 years. The 1 year mortality of 27% and a 5 year mortality of 45% are similar to current American Heart Association statistics.

**Prognostication**

Despite the overall relatively poor outlook for patients with heart failure, prognostication on an individual basis is difficult. Models to assess prognosis have been developed, yet each has specific limitations, particularly in the elderly patient population with multiple comorbidities and frailty where the 1 year mortality risk may be close to 50%. Given this prognostic ambiguity, health professionals remain unclear as to when to involve specialist palliative care or initiate end-of-life approaches. In spite of being subject to progressive physical disability, and having survived many clinical crises, patients frequently fail to appreciate the seriousness of their condition, and later, their families are often shocked by what they perceive as an unexpected death.

The European Society of Cardiology (ESC) guidelines recognize this difficulty in deciding when patients require specialist palliative or end-of-life care. However, they provide some advice to help clinicians identify patients that should be considered for referral to a specialist palliative care or end-of-life service (Box 2).

**Box 2. Suggested criteria for referral to specialist palliative care service**

- Frequent readmission to hospital within past 12 months
- Frequent decompensation of chronic heart failure
- New York Heart Association Class IV
- Progressive decline in quality of life

The patients’ perspective of heart failure can be found in studies that have specifically sought their opinion, and these generally employ a qualitative research methodology. Whilst their study design does not set out to produce results that are statistically generalizable, key themes have emerged: That patients often experience barriers to open communication with healthcare professionals, including an inability to talk freely with clinicians and to ask questions about prognosis, together with a sense that information is being withheld. This may reflect an understandable reluctance of healthcare professionals to initiate discussion on end-of-life issues, either as a manifestation of their own attitudes to death or dying or anxiety about undermining patient’s trust or hopes for the future. In addition, patients describe professionally driven healthcare services that focus on delivering guideline-based medical treatment. This is sometimes burdensome in itself, and there is often poor co-ordination and a lack of continuity.
of care.\textsuperscript{16,21,22} Heart failure management programmes have been developed in several countries to address many of these issues. Despite this, patients continue to experience an ongoing need for better communication and experience a high symptom prevalence and burden.

**Needs assessment in heart failure**

Multiple studies have described the symptom burden associated with heart failure and the impact on health status and quality of life. These studies illustrate how patients experience a high number of symptoms, many of which they also find highly distressing\textsuperscript{2–5} (Table 1). Here, we focus on physical and psychological symptoms.

More than two decades ago, large surveys reported a high burden of symptoms and concerns in patients with advanced heart failure.\textsuperscript{23,24} The most commonly reported symptom was pain, and this was also found to be very distressing in 50% of patients. Forty three per cent reported dyspnoea. Emotional symptoms were also reported with low mood in 59% and high levels of anxiety in 45% of patients. Other symptoms, albeit less frequently reported, included urinary incontinence, constipation, and nausea. In those patients admitted to hospital, the management of these symptoms was optimized but brought little relief: 35% still experienced distressing pain, 31% constipation, 24% dyspnoea, and 24% nausea.\textsuperscript{23} Data from the Study to Understand Prognosis andPreferences for Outcomes and Risks of Treatments (SUPPORT) of the last 6 months of life show that these symptoms increase in frequency close to death. In the final 3 days of life, as many as 63% reported extreme shortness of breath.\textsuperscript{24} Whilst in recent years, the need to address symptom prevalence and relief in advanced heart failure has received a greater emphasis, many patients still experience a spectrum of refractory malaise.

More recently Blinderman and colleagues studied a sample of 103 patients in the USA.\textsuperscript{20} The mean age was 67 years, 72% male, and all were in NYHA class III/IV. The most prevalent symptoms reported by more than half of this population were lack of energy, dry mouth, shortness of

| Table 1 Goals of palliative care |
|---------------------------------|
| Lokker et al.\textsuperscript{2}  |
| Blinderman et al.\textsuperscript{3} |
| Zambroski et al.\textsuperscript{4}  |
| Wilson and McMillan\textsuperscript{5} |
| n = 230 | n = 103 | n = 53 | n = 40 |
| **Physical problems** | **Frequency (%)** | **High distress (%)** | **Frequency (%)** | **High distress (%)** | **Frequency (%)** | **High distress (%)** | **Frequency (%)** | **High distress (%)** |
| Shortness of breath | 95.2 | 89 | 56.3 | 43.1 | 85.2 | 60.5 | 65 |
| Feeling drowsy/tired | 93.0 | 83 | 52.4 | 24.1 | 67.9 | 37.1 | 72.5 |
| Pain | 91.3 | 76 | 37.9 | 54.1 | 57.4 | 51.7 | 52.5 |
| ‘I don’t look like myself’ | 90.4 | 81 | 25.2 | 23.1 |
| Weight loss | 84.8 | 51 | 19.4 | 25 | 32.1 | 18.8 | 52.5 |
| Lack of energy | 82.2 | 67 | 66 | 44.8 | 84.9 | 63.6 | 70 |
| Swelling arms/legs | 81.3 | 70 | 32 | 33.3 | 47.2 | 30.4 | 47.5 |
| Difficulty sleeping | 77.0 | 64 | 44.1 | 44.4 | 64.2 | 60.6 | 52.5 |
| Tingling hands/feet | 73.5 | 66 | 48.5 | 22 | 46.2 | 47.8 | 55 |
| Changes in way food tastes | 73.0 | 61 | 15.5 | 18.5 | 18.9 | 44.4 | 50 |
| Lack of appetite | 72.2 | 53 | 31.1 | 25.8 | 30.2 | 40 | 37.5 |
| Difficulty concentrating | 67.4 | 30 | 33 | 29.4 | 50 | 44 | 40 |
| Problems with sexual interest/activity | 52.6 | 8 | 26 | 46.2 | 46.3 | 50 | 17.5 |
| Cough | 49.1 | 33 | 40.8 | 16.7 | 57.4 | 14.8 | 45 |
| Nausea | 42.2 | 23 | 41.5 | 19 | 20 |
| Dizziness | 41.3 | 19 | 27.2 | 32.1 | 51.9 | 38.5 | 45 |
| Feeling bloated | 36.1 | 19 | 28.2 | 17.2 | 51.9 | 40 | 25 |
| Dry mouth | 35.7 | 15 | 62.1 | 14.1 | 74.1 | 33.3 | 72.5 |
| Problems urinating | 32.2 | 16 | 26.2 | 29.6 | 24.1 | 27.3 | 17.5 |
| Itching | 28.3 | 8 | 34.3 | 22.9 | 43.4 | 47.4 | 40 |
| Constipation | 26.1 | 15 | 25.2 | 38.5 | 26.4 | 30.8 | 30 |
| Vomiting | 25.7 | 13 | 24.1 | 33.3 | 10 |
| Sweats | 25.2 | 15 | 21.4 | 18.2 | 53.7 | 42.9 | 27.5 |
| Diarrhoea | 12.2 | 18 | 22.2 | 10 | 17.5 |
| **Psychological problems** | **Frequency (%)** | **High distress (%)** | **Frequency (%)** | **High distress (%)** | **Frequency (%)** | **High distress (%)** | **Frequency (%)** | **High distress (%)** |
| Worrying | 94.3 | 30 | 43.7 | 32.3 | 61.5 | 53.3 | 50 |
| Feeling irritable | 93.5 | 28 | 33 | 26.5 | 53.7 | 34.6 | 32.5 |
| Feeling sad | 93 | 18 | 42.7 | 34.1 | 54.7 | 44 | 37.5 |
| Feeling nervous | 92.2 | 50 | 35.9 | 38.9 | 53.7 | 38.5 | 30 |
breath, and drowsiness. Less commonly reported symptoms included numbness or tingling in hands and feet, insomnia, cough, and anorexia. The patients also described various psychological symptoms: worrying, sadness, nervousness, difficulty concentrating, and feeling irritable. Alongside this high symptom prevalence, they described high levels of symptom intensity, frequency, and associated distress. High levels of distress were associated with symptoms of lack of energy, dry mouth, shortness of breath, and feeling drowsy and pain (Table 1).

Most studies of symptom prevalence in heart failure have been based on a typical elderly, predominantly male patient population, living with left ventricular dysfunction in the developed world. Whilst the prevalence of heart failure in developing countries is also high, a different aetiological background, including infectious and tropical diseases, more maternal ill health, and poorly controlled hypertension, leads to a younger demographic with a different gender bias. Despite these differences, a similar pattern of heart failure symptom and burden is emerging. A recent study of 230 patients with advanced heart failure attending a public hospital in South Africa reported on symptom prevalence and burden in younger patients. The mean age of the study population was 58 years, 127 (55%) female, and few patients had multiple comorbidities (mean two comorbidities). All were symptomatic on at least minimal exercise (NYHA class III, 90%; NYHA IV, 10%) and required considerable assistance to undertake the activities of daily life and were unable to work and required frequent medical care (Karnofsky Performance Status Score, mean score 50%). The patients reported a high prevalence of symptoms. Prominent physical symptoms included shortness of breath and feeling drowsy/tired and pain. In this younger population, urinary incontinence was also reported by 32% and constipation in 26%. Psychological symptoms with the highest prevalence included worrying, feeling irritable, and feeling sad. Symptoms of ‘shortness of breath’, ‘numbness/tingling in hands or feet’, and ‘I do not look like myself’ were described as most distressing (Table 1).

Alongside physical symptoms, there is a deleterious effect on psychological wellbeing. Depression is common in heart failure, likely applicable to at least a third of patients. Some depressive symptoms may overlap with symptoms of advanced heart failure, such as tiredness. However, even when taking such confounding factors into account and excluding these items from data analysis, studies still report high levels of depression in heart failure, possibly affecting as many as 50%.25

Many patients experience multiple symptoms simultaneously which exacerbates their symptom burden. A recent survey of more than 700 patients with heart failure recruited from the USA, the Netherlands, Sweden, and Asia reported a cluster of physical symptoms that included dyspnoea, difficulty in walking or climbing, fatigue/increased need to rest, and fatigue/low energy. Worrying, feeling depressed, cognitive problems, and sleep difficulties formed an emotional symptomatic cluster.26 The authors report few cultural differences in the components of these symptom clusters. Whilst some of these clusters are interrelated, they do not necessarily share a common mechanism or trigger. Symptomatic clustering will no doubt influence the patient’s ability to self-manage their heart failure; maintain physical, mental, and social functioning; and increase the complexity of the intervention required to comprehensively deal with individual need. This all points to the need to consider a more nuanced approach to their care, taking into account these sometimes subtle but important differences, and facilitate provision of a personalized treatment plan consistent with their specific concerns.

**Integrating palliative care into heart failure care**

Given the poor survival rates from heart failure and the high prevalence of symptoms, the need to integrate a palliative care approach into the overall heart failure patient pathway is clear. Palliative care is recognized in international heart failure guidelines.11,27 The Heart Failure Association (HFA) of the ESC issued a position statement in 2009,28 and the most recent ESC heart failure guidelines of 2016 acknowledge the value of including palliative care but stop short of providing a recommendation with a level of evidence.12 In contrast, the 2013 heart failure guidelines from the American Heart Association and American College of Cardiology recommend palliative care to improve quality of life in symptomatic patients based on perceived patient benefit. They advise that this should be incorporated in discharge planning (Class 1; level of evidence B).27

Despite this recognition, few patients are referred to specialist palliative care services. Turning again to data from the UK, the National Heart Failure Audit data from 2013 to 2014 report that only 4% of patients with heart failure were referred to specialist palliative care services, a proportion which has been relatively constant over several years.7 Whilst not significantly different from the earlier reported 5% threshold of need,3 this low referral rate to specialist palliative care services likely represents an under provision of support for these acute heart failure patients who may have particularly complex needs. However, heart failure nurses in the UK provide comprehensive disease management and view the provision of general palliative care as a major component of their role. Following an educational initiative from the British Heart Foundation and fostering links with specialist palliative care through a multi-disciplinary team approach, their delivery of general palliative care has increased in recent years.29 Limited access to similar collaborative heart failure disease management programmes and variation in team roles and responsibilities across Europe may result in some
patients and their families being denied this much needed level of support.

**Implanted electronic and mechanical assist devices**

Dilemmas related to the handling of implanted device therapy in the face of progressive heart failure or the occurrence of another life limiting disease are worthy of special mention in relation to palliative and end-of-life care. There has been an exponential increase in the rates of use of implantable cardioverter defibrillators, and cardiac resynchronization therapy with defibrillators as evidence for benefit has accrued. At the point of implantation, discussion tends to be framed around the protection conferred by having the device. To the patient, the decision is often binary in accepting the device or anticipating an avoidable death. The possibility of later device deactivation in the face of clinical decline towards the end of life is rarely broached. Similarly, the informed consent process tends to concentrate on peri-procedural and short-term risk rather than considering events, sometimes perceived as hypothetical, later in the course of life. Evidence suggests that patients and families sometimes anticipate later adverse clinical scenarios and show a willingness to confront these issues at the time of implantation. Guidelines issued by the European Heart Rhythm Association suggest that end-of-life issues should be incorporated in pre-implant discussions and revisited at intervals along the heart failure disease trajectory. Many studies have demonstrated that discussion of device deactivation, if it takes place at all, may occur very close to the point of death. Advance care planning might obviate some of these problems but has been little espoused by heart failure patients. When these instruments are used, they tend to be generic with little attention to device-specific preferences. Decisions on device deactivation should be undertaken at times when there is access to the equipment and personnel with the required expertise to facilitate this process. Many reports describe patient and family distress as shocks are administered during the active dying phase, even when a ‘do not resuscitate’ order is in place.

For those with left ventricular assist devices, implanted either as a bridge to transplantation or as destination therapy, liaison with palliative care is appropriate. Inter-professional discussion is relevant pre-implantation, and palliative care involvement is certainly critical when withdrawing therapy.

**Challenges to integrating palliative care and heart failure**

The need to increase the emphasis on palliative and end-of-life care has been identified as a policy recommendation that is necessary to improve care to patients with heart failure: a document endorsed by the HFA alongside 49 national heart failure working groups. However, this will require several challenges to be overcome.

Integrating heart failure and palliative care remains difficult, with insufficient evidence to allow us to currently recommend any specific model. Examples of good practice do exist and describe the provision of heart failure palliative care based on local service configuration. One service adopted a shared care approach by a cardiologist and palliative care physician, with the heart failure nurse specialist acting as a key worker and liaising among local medical care, hospital specialists, and hospice services. A small pilot study of integrated palliative advanced home care and heart failure care study in Sweden (PREFER study) randomized 72 patients with advanced heart failure to usual care or care provided by palliative and heart failure specialists (physicians and nurses). The intervention included patient education around heart failure self care, advanced care planning, and frequent needs assessment that included physical, psychological, social, and spiritual issue needs. Needs assessment focused on heart failure and other comorbidities. The patients randomized to receive the intervention experienced a significant reduction in nausea (P = 0.02), better quality of life (P = 0.05), fewer hospitalizations (P = 0.009), and fewer days in hospital (103 vs. 305). Symptom relief was aided by the administration of intravenous diuretics at home but was fairly labour intensive, some patients requiring several home visits each day. Additional studies on similar initiatives are currently underway. When reported in full, they should add to our knowledge and help to inform guidance on how best to integrate palliative and heart failure care.

Providing palliative care alongside optimal heart failure management is difficult, and sometimes, the ethos of palliative care and cardiology seem to be at odds. Rather than working in silos, a multi-disciplinary approach is applicable, garnering and synergizing the skills of both specialties so that patient care is optimized throughout the course of the illness.

**Conflict of interest**

None declared.
References

1. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol 2014; 171: 368–76.

2. Lokker ME, Gwyther I, Riley JP, van Zuylen L, van fer Heide A, Harding R. The prevalence and associated distress of physical and psychological symptoms in patients with advanced heart failure attending a South African medical center. J Cardiovasc Nurs 2016; 31: 313–322.

3. Blinderman CD, Homel P, Billings A, Porenoy RK, Tennstedt SL. Symptom distress and quality of life in patients with advanced congestive heart failure. J Pain Symptom Manage 2008; 35: 594–603.

4. Zambroski C, Moser D, Bhat G, Ziegler C. Impact of symptom prevalence and symptom burden on quality of life in patients with heart failure. Eur J Cardiovasc Nurs 2005; 4: 198–206.

5. Wilson A, McMillan S. Symptoms experienced by heart failure patients in hospice care. J Hosp Palliat Nurs 2013; 15: 13–21.

6. Goodlin SJ. Palliative care in congestive heart failure. J Am Coll Cardiol 2009; 54: 380–96.

7. Adler ED, Gold JW, Hardman S, Cleland JGF, Dargie H, van Zuylen L, van fer Heide A, Harding R. The prevalence and associated distress of physical and psychological symptoms in patients with heart failure: before, during and after hospitalization. ESC Heart Fail 2014; 1: 110–145.

8. World Health Organisation. Global Atlas of Palliative Care at the End of Life. World health Organisation 2014 ISBN: 978-0-9928277-0-0

9. Howie MR, Anker SD, Cleland JFG, Felker GM, Filippatos G, Jaarsma T, Jourdian P, Knight E, Massie B, Ponikowski P, Lopez-Sendon J. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail 2014; 1: 4–25.

10. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Forre TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohole LE, Samal UC, Shimokawa H, Siwanto BS, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail 2014; 1: 4–25.

11. Cleland JGF, Dargie H, Hardman S, McDonagh T, Michell P. National Heart Failure Audit. April 2013–March 2014. London: National Institute for Cardiovascular Outcomes Research 2015.

12. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kannel WB, Lackland DT, Lefevre ML, Lissner LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muss頓 P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sirtori PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JV, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015; 131: e29–322.

13. Levy WC, Mozaffarian D, Linker DT, Sutrathar SC, Anker SD, Crop AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson P, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424–1433.

14. Cleland JG, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ. The National Heart Failure Audit for England and Wales 2008–2009. Heart 2011; 97: 876–86.

15. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Roman Gonzalez-Juanatey J, Harjola V, Jankowski E, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieles B, Riley JP, Rosano G, Ruiolle LM, Ruschitzka F, Rutten FH, van der Meer P. Task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology, 2016. Eur J Heart Fail 2016; 18: 2129–2200.

16. Rogers AE, Addition-Hall JM, Aberj AJ, McCoy ASM, Bulpitt C, Coats AJ, Gibbs JS. A qualitative study of chronic heart failure patients’ understanding of their symptoms and drug therapy. Eur J Heart Fail 2002; 4: 283–287.

17. Boyd K, Murray SA, Kendall M, Worth A, Benton TF, Clausen H. Living with advanced heart failure: a prospective community based study of patients and their carers. Eur J Heart Fail 2004; 6: 585–591.

18. Harding R, Selman L, Beynon T, Hodson F, Coady E, Read C, Walton M, Gibbs L, Higginson JJ. Improving end-of-life care for patients with chronic heart failure: ‘let’s hope it will get better, when I know in my heart of hearts it won’t’. Heart 2007; 93: 963–7.

19. Davidson PM. Difficult conversations and chronic heart failure: do you talk or walk the walk? Curr Opin Support Palliat Care 2007; 1: 274–8.

20. Gallacher K, May CR, Montori VM, Mais PS. Understanding patients’ experiences of treatment burden in chronic heart failure using normalization process theory. Ann Fam Med 2011; 9: 235–43.

21. Low J, Pattenden J, Candy B, Beattie JM, Jones L. Palliative care in advanced heart failure: an international review of the perspectives of recipients and health professionals on care provision. J Card Fail 2011; 17: 231–52.

22. McCarthy M, Lay M, Addington-Hall J. Dying from heart disease. J Roy Coll Phys 1996; 30: 325–328.

23. Levenson JW, McCarthy EP, Lynn J, Davis RB, Phillips RS. The last six months of life for patients with congestive heart failure. J Am Geriatr Soc 2000; 48: S101–109.

24. Lokker ME, Gwyther I, Magona P, Riley JP, van Zuylen L, van fer Heide A, Harding R. Depressive symptoms in patients with advanced heart failure attending a South African public hospital. Eur J Heart Fail 2014; 16: S127–127.

25. Moser D, Lee KS, Wu J, Mudd-Martin G, Jaarsma T, Huang T, Fan X, Stromberg A, Lennie T, Riegel B. Identification of symptom clusters among patients with heart failure: an international observational study. Int J Nurs Stud 2014; 51: 1366–1372.

26. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013; 62: e147–239.

27. Jaarsma T, Beattie JM, Ryder M, Rutten FH, McDonagh T, Mohacsi P, Murray SA, Grodzicki T, Bergh I, Metra M, Eklman I, Angermann C, Leventhal M, Pitis A, Anker SD, Gavazzi A, Ponikowski P, Dickstein K, Delacretaz E, Blue L, Strasser F, McMurray J; Advanced Heart Failure Study Group of the HFA of the ESC. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 433–43.

28. Johnson MJ, MacCallum A, Butler J, Rogers A, Sam E, Fuller A, Beattie JM. Heart failure specialist nurses’ use of palliative care services: a comparison of surveys across England in 2005 and 2010. Eur J Cardiovasc Nurs 2012; 11: 190–6.

29. Kirkpatrick JN, Gottlieb M, Sehgal P, Patel R, Verdinon RJ. Desactivation of implantable cardioverter defibrillators in terminal illness and end of life care. Am J Cardiol 2012; 109: 91–4.

30. Raphael CE, Ko-A, Wing M, Stain N, Wright I, Francis DP, Kanagaratnam P.
Implantable cardioverter-defibrillator recipient attitudes towards device deactivation: how much do patients want to know? Pacing Clin Electrophysiol 2011; 34: 1628–33.

32. Padeletti L, Arnar DO, Boncinelli L, Brachman J, Camm JA, Daubert JC, Hassam SK, Deliens L, Glikson M, Hayes D, Israel C, Lampert R, Lobban T, Raatikainen P, Siegal G, Vardas P; Reviewers:, Kirchhof P, Becker R, Cosio F, Loh P, Cobbe S, Grace A, Morgan J. European Heart Rhythm Association; Heart Rhythm Society. EHRA expert consensus statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12: 1480–9.

33. Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med 2004; 141: 835–8.

34. Tajouri TH, Ottenberg AL, Hayes DL, Mueller PS. The use of advance directives among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 2012; 35: 567–573.

35. Westerdahl AK, Sutton R, Frykman V. Deﬁbrillator patients should not be denied a peaceful death. Int J Cardiol 2015; 182: 440–6.

36. Johnson M, Nunn A, Hawkes T, Stockdale S, Daley A. Planning for end-of-life care in heart failure: experience of two integrated cardiology-palliative care teams. Br J Cardiol 2012; 19: 71–5.

37. Bränström M, Boman K. Effect of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomised controlled study. Eur J Heart Fail 2014; 16: 1142–115.

38. Campbell RT, Jackson CE, Wright A, Gardner RS, Ford I, Davidson PM, Denvir MA, Hogg KJ, Johnson MJ, Petrie MC, McMurray JV. Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. ESC Heart Fail 2015; 2: 25–36.